Patent US5158871A successfully refreshed from Google Patents.
US5158871A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of using magnetic particles for isolating, collecting and assaying diagnostic ligates
Assignee: CONNECTICUT A CORP OF CT, University of
•
Filing: 1989-02-02
•
Granted: 1992-10-27
•
Expires: 2009-02-02
Abstract
Abstract An in vivo method for preparing, inserting, isolating, collecting and assaying diagnostic ligates present in body fluids. Magnetically responsive particles with attached ligands specific for a particular ligate are introduced into the body fluid. Bonding between the ligand and ligate results in particle/ligand/ligate complexes. The complexes are removed by the application of a magnetic field and the complexes are permitted to cluster. The clusters are then quantitated to determine the concentration of the ligate in the body fluid. Associated materials and devices useful in the practice of this method are also provided.
Inventors
- 👤 Edward F. Rossomando
- 👤 Jane Hadjimichael
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 07:59
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/54313; G01N33/54326; G01N33/68; G01N33/6863; G01N33/6893; G01N35/00; G01N35/0098; Y; Y10; Y10S; Y10S435/00; Y10S435/971; Y10S436/00; Y10S436/811
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
173 words
A method of determining the amount of a ligate in a fluid which comprises: attaching a first ligand comprising a monoclonal antibody specific for the ligate to magnetically responsive particles; introducing the magnetically responsive particles with attached first ligand into the fluid; allowing the magnetically responsive particles with attached first ligand to bind to the ligate so that magnetic particle/ligand/ligate complexes are formed; retrieving the complexes from the fluid by means of a magnetic field; resuspending the retrieved complexes; aggregating the resuspended complexes to form suspended clusters by adding aggregating particles to said complexes, said aggregating particles comprising a magnetically responsive particle with an attached second ligand which specifically binds to said ligate, wherein said second ligand is different from said first ligand and wherein said clusters comprise at least one of said complexes and at least one of said aggregating particles; allowing the suspended clusters to settle onto a support surface, and determining the amount of oligate retrieved from the fluid by visually detecting said clusters with the aid of a microscope.
Claim 2
Independent Claim
173 words
A method of determining the amount of a ligate in a fluid which comprises: attaching a first ligand comprising a monoclonal antibody specific for the ligate to magnetically responsive particles; introducing the magnetically responsive particles with attached first ligand into the fluid; allowing the magnetically responsive particles with attached first ligand to bind to the ligate so that magnetic particle/ligand/ligate complexes are formed; retrieving the complexes from the fluid by means of a magnetic field; resuspending the retrieved complexes; aggregating the resuspended complexes to form suspended clusters by adding aggregating particles to said complexes, said aggregating particles comprising a magnetically responsive particle with an attached second ligand which specifically binds to said ligate, wherein said second ligand is different from said first ligand and wherein said clusters comprise at least one of said complexes and at least one of said aggregating particles; allowing the suspended clusters to settle onto a support surface, and determining the amount of oligate retrieved from the fluid by visually detecting said clusters with the aid of a microscope.
Claim 3
Dependent Claim
31 words
The method of claim 1 wherein the step of attaching the ligand is further characterized in that the ligand is attached to the magnetically responsive particle through a protein A linker.
Claim 4
Dependent Claim
54 words
The method of claim 1 wherein the step of determining the amount of ligate retrieved from the fluid is further characterized in that the clusters visible under the microscope form an image which is recorded on a suitable storage medium and the number of clusters present in the image is determined by computerized counting.
Claim 5
Independent Claim
202 words
A method of screening for periodontal disease which comprises: attaching a first ligand comprising a monoclonal antibody specific for a ligate present in the gingival crevicular fluid and indicative of periodontal disease, which is selected from the group consisting of cachectin and interleukin 1, to a magnetically responsive particle; introducing the magnetically responsive particle with attached first ligand into the gingival crevicular sulcus; allowing the magnetically responsive particles with attached first ligand to bind to the ligate so that magnetic particle/ligand/ligate complexes are formed; retrieving the complexes from the gingival crevicular sulcus by means of a magnetic field; resuspending the retrieved complexes; aggregating the resuspended complexes to form suspended clusters by adding aggregating particles to said complexes, said aggregating particles comprising a magnetically responsive particle with attached second ligand which specifically binds to said ligate, wherein said second ligand is different from said first ligand, and wherein said clusters comprise at least one of said complexes and at least one of said aggregating particles; allowing the suspended clusters to settle onto a support surface, and determining the amount of the ligate indicative of periodontal disease retrieved from the gingival crevicular fluid by visually detecting said clusters with the aid of a microscope.
Claim 6
Independent Claim
202 words
A method of screening for periodontal disease which comprises: attaching a first ligand comprising a monoclonal antibody specific for a ligate present in the gingival crevicular fluid and indicative of periodontal disease, which is selected from the group consisting of cachectin and interleukin 1, to a magnetically responsive particle; introducing the magnetically responsive particle with attached first ligand into the gingival crevicular sulcus; allowing the magnetically responsive particles with attached first ligand to bind to the ligate so that magnetic particle/ligand/ligate complexes are formed; retrieving the complexes from the gingival crevicular sulcus by means of a magnetic field; resuspending the retrieved complexes; aggregating the resuspended complexes to form suspended clusters by adding aggregating particles to said complexes, said aggregating particles comprising a magnetically responsive particle with attached second ligand which specifically binds to said ligate, wherein said second ligand is different from said first ligand, and wherein said clusters comprise at least one of said complexes and at least one of said aggregating particles; allowing the suspended clusters to settle onto a support surface, and determining the amount of the ligate indicative of periodontal disease retrieved from the gingival crevicular fluid by visually detecting said clusters with the aid of a microscope.
Claim 7
Dependent Claim
42 words
The method of claim 4 wherein the step of retrieving the particle/ligand/ligate complexes is further characterized in that the complexes are retrieved by means of a magnetic harvester comprising a hand-held electromagnet having an attached tip anatomically compatible with the oral cavity.
Claim 8
Dependent Claim
32 words
The method of claim 4 wherein the step of attaching the first ligand to the magnetically responsive particle is further characterized in that the first ligand is an immunoglobulin G monoclonal antibody.
Claim 9
Dependent Claim
36 words
The method of claim 4 wherein the step of aggregating the complexes to form clusters is further characterized in that the second ligand comprises polyclonal antibodies which specifically bind to the ligate indicative of periodontal disease.
Claim 10
Dependent Claim
27 words
The method of claim 4 wherein the step of aggregating the complexes to form clusters is further characterized in that the complexes are resuspended in a buffer.
Claim 11
Dependent Claim
16 words
The method of claim 8 further characterized in that said buffer is 0.5 m Tris HCL.
Claim 12
Dependent Claim
15 words
The method of claim 8 further characterized in that the buffer includes a nonimmunologically-reactive protein.
Claim 13
Dependent Claim
16 words
The method of claim 10 further characterized in that said nonimmunologically-reactive protein is bovine serum albumin.
Claim 14
Dependent Claim
14 words
The method of claim 8 further characterized in that the buffer includes a surfactant.
References Cited (Backward Citations)
US4279617A
Cited
EP0030087A1
Cited
US4486530A
Cited
US4452773A
Cited
EP0194156A1
Cited
US4741999A
Cited
WO1989001161A1
Cited
JPH02287159A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-27 | 1996-04-27 | 1996-10-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-27 | 2000-04-27 | 2000-10-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-27 | 2004-04-27 | 2004-10-27 | $7700.00 | Window Closed / Lapsed |